ZA988664B - Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions - Google Patents

Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions

Info

Publication number
ZA988664B
ZA988664B ZA988664A ZA988664A ZA988664B ZA 988664 B ZA988664 B ZA 988664B ZA 988664 A ZA988664 A ZA 988664A ZA 988664 A ZA988664 A ZA 988664A ZA 988664 B ZA988664 B ZA 988664B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical compositions
dry powder
protease inhibitor
powder pharmaceutical
secretory leukocyte
Prior art date
Application number
ZA988664A
Other languages
English (en)
Inventor
Ralph W Niven
Clifford D Wright
Byeong S Chang
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ZA988664B publication Critical patent/ZA988664B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA988664A 1997-10-03 1998-09-22 Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions ZA988664B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/943,759 US20010006939A1 (en) 1997-10-03 1997-10-03 Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions

Publications (1)

Publication Number Publication Date
ZA988664B true ZA988664B (en) 1999-04-06

Family

ID=25480210

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA988664A ZA988664B (en) 1997-10-03 1998-09-22 Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions

Country Status (9)

Country Link
US (2) US20010006939A1 (ja)
EP (2) EP1030683A1 (ja)
JP (2) JP2001518518A (ja)
KR (1) KR20010024395A (ja)
CN (1) CN1327452A (ja)
AU (2) AU738298B2 (ja)
CA (1) CA2308123A1 (ja)
WO (2) WO1999017800A1 (ja)
ZA (1) ZA988664B (ja)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043308A2 (en) * 1998-02-27 1999-09-02 Marlene Rabinovitch Treating pulmonary hypertension through tenascin suppression and elastase inhibition
JP5704780B2 (ja) * 1999-08-13 2015-04-22 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 脈管形成因子の用量および心筋血流を改善するための投与方法
AU7957700A (en) 1999-10-26 2001-05-08 Japan Tissue Engineering Co., Ltd. Wound contraction inhibitors
AU1628101A (en) * 1999-11-22 2001-06-04 Millennium Pharmaceuticals, Inc. Jaffa, a novel fibroblast growth factor family member and uses therefor
WO2001051030A1 (en) * 2000-01-10 2001-07-19 Dura Pharmaceuticals, Inc. Pharmaceutical formulation and method for pulmonary and oral delivery
WO2001052883A1 (en) * 2000-01-20 2001-07-26 Amgen Inc. Inhibitors of protease-activated receptor-2 (par-2) as novel asthma therapeutics
AU2001241913A1 (en) * 2000-03-01 2001-09-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for wound treatment
WO2001092522A2 (en) * 2000-06-01 2001-12-06 Eli Lilly And Company Human fgf-20 nucleic acids and polypeptides
DE10101792B4 (de) * 2001-01-17 2004-03-18 Vivotec Biomedical Technologies Gmbh Verfahren zum Nachweis von Pankreaskarzinom oder chronischer Pankreatitis und Verwendung von Antikörpern
JP5154732B2 (ja) * 2001-02-06 2013-02-27 イノバータ・バイオメッド・リミテッド 薬剤
WO2003018620A2 (en) * 2001-08-27 2003-03-06 Les Laboratoires Aeterna Inc. Serine protease inhibitor and processes for the preparation thereof
EP1479300B1 (en) * 2002-02-22 2009-10-21 Ajinomoto Co., Inc. Amino acid powder and process for producing the same
GB0226274D0 (en) * 2002-11-11 2002-12-18 Medpharm Ltd Metered dose inhalation preparations
GB0309064D0 (en) * 2003-04-22 2003-05-28 Univ Manchester Modified peptides and their uses
EP1660661A2 (en) * 2003-08-08 2006-05-31 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
SI1656455T1 (sl) * 2003-08-13 2012-12-31 Sandoz Ag Postopek za čiščenje rekombinantnih polipeptidov
CA2545855A1 (en) * 2003-11-14 2005-06-02 Baxter International Inc. Alpha 1-antitrypsin compositions and treatment methods using such compositions
GB0328629D0 (en) * 2003-12-10 2004-01-14 Medpharm Ltd Metered dose inhalation preparations
AU2005221151A1 (en) 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
US20080181892A1 (en) * 2004-08-11 2008-07-31 Trubion Pharmaceuticals Binding Domain Fusion Protein
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
US20060134008A1 (en) * 2004-12-16 2006-06-22 Daniel Deaver Compositions and methods for pulmonary conditions
CN101401001A (zh) * 2006-01-12 2009-04-01 詹森药业有限公司 分泌性白细胞蛋白酶抑制剂通过糜酶的加工
US8725529B2 (en) * 2008-12-30 2014-05-13 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US8712794B2 (en) * 2008-12-30 2014-04-29 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US8706518B2 (en) * 2008-12-30 2014-04-22 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US20100168525A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US8694330B2 (en) * 2008-12-30 2014-04-08 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US20100168602A1 (en) * 2008-12-30 2010-07-01 Searete Llc Methods and systems for presenting an inhalation experience
US20100163038A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US9750903B2 (en) * 2008-12-30 2017-09-05 Gearbox, Llc Method for administering an inhalable compound
US20100163036A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US8738395B2 (en) * 2008-12-30 2014-05-27 The Invention Science Fund I, Llc Methods and systems for presenting an inhalation experience
US20100163024A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Methods and systems for presenting an inhalation experience
US20100163025A1 (en) * 2008-12-30 2010-07-01 Searete Llc Methods and systems for presenting an inhalation experience
US20100163027A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100168529A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100163033A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100169259A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100163034A1 (en) * 2008-12-30 2010-07-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for presenting an inhalation experience
US20100169260A1 (en) * 2008-12-30 2010-07-01 Searete Llc Methods and systems for presenting an inhalation experience
RU2657523C2 (ru) * 2011-11-03 2018-06-14 Олег Петрович Жирнов Фармацевтический аэрозольный состав ингибиторов протеаз с озон-сберегающим пропеллентом и его получение
AU2018261021A1 (en) * 2017-05-05 2019-12-12 Trefoil Therapeutics, Inc. Recombinant modified fibroblast growth factors and therapeutic uses thereof
WO2019046664A1 (en) * 2017-08-30 2019-03-07 Applied Biological Laboratories, Inc. COMPOSITIONS AND METHODS FOR PROTECTING AGENTS FROM PATHOGENS AND IRRITANTS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE556587A (ja) * 1957-01-31 1957-04-11
US4678812A (en) * 1986-05-30 1987-07-07 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
JPH05963A (ja) * 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
JP3385040B2 (ja) * 1991-02-14 2003-03-10 武田薬品工業株式会社 グリア活性化因子およびその製造法
US6005100A (en) * 1992-12-02 1999-12-21 Kabushiki Kaisha Hayashibara Seitbutsu Kagaku Kenkyujo Trehalose composition for prolonging product shelf life
JP3168550B2 (ja) * 1992-12-02 2001-05-21 株式会社林原生物化学研究所 脱水剤およびそれを用いる含水物の脱水方法並びにその方法で得られる脱水物品
UA46706C2 (uk) * 1993-03-26 2002-06-17 Амген Інк. Спосіб лікування та запобігання хворобливому стану пацієнта, фармацевтична композиція
US5633227A (en) * 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5876992A (en) * 1996-07-03 1999-03-02 Molecular Biology Resources, Inc. Method and formulation for stabilization of enzymes

Also Published As

Publication number Publication date
EP1030683A1 (en) 2000-08-30
AU8923998A (en) 1999-04-27
US20020010318A1 (en) 2002-01-24
JP2001519142A (ja) 2001-10-23
AU8914998A (en) 1999-04-27
AU738298B2 (en) 2001-09-13
KR20010024395A (ko) 2001-03-26
US20010006939A1 (en) 2001-07-05
EP1025122A1 (en) 2000-08-09
CA2308123A1 (en) 1999-04-15
WO1999018128A1 (en) 1999-04-15
WO1999017800A1 (en) 1999-04-15
JP2001518518A (ja) 2001-10-16
CN1327452A (zh) 2001-12-19

Similar Documents

Publication Publication Date Title
ZA988664B (en) Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
HUP0104768A3 (en) 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same
HUP0105077A3 (en) Serine protease inhibitors and pharmaceutical compositions containing them
PL331531A1 (en) Pharmaceutical aerosol compositions
ZA983843B (en) Protease inhibitors
PL336589A1 (en) Serinic protease inhibitors
GB9727053D0 (en) Pharmaceutical compositions
CY2569B1 (en) Pharmaceutical compositions
HUP0002247A3 (en) Protease inhibitors
PL337755A1 (en) Protease inhibitors
IL132629A0 (en) Protease inhibitors
HK1021700A1 (en) Novel powder compositions
ZA988479B (en) Protease inhibitors
IL131995A0 (en) Gastric-retained pharmaceutical compositions
GB9723985D0 (en) Pharmaceutical compositions
ZA9811532B (en) Pharmaceutical compositions
ZA988064B (en) Protease inhibitors
IL122591A0 (en) Pharmaceutical compositions comprising cystein protease inhibitors
HU9700632D0 (en) Pharmaceutical compositions
HUP0001976A3 (en) Antiviral protease inhibitors and pharmaceutical compositions
EP0975612A4 (en) PROTEASE INHIBITORS
ZA982117B (en) Pharmaceutical compositions
GB9718270D0 (en) Pharmaceutical compositions
GB9722066D0 (en) Pharmaceutical compositions
GB9710527D0 (en) Pharmaceutical compositions